Sarepta Therapeutics Inc. (SRPT) announced after the bell Wednesday that results from a Phase 2b study of eteplirsen in patients with Duchenne muscular dystrophy through more than two years showed a continued stabilization of walking ability on the 6-minute walk test. The stock is now up 1.02 on 217K shares.
Sarepta Therapeutics fell during the first half of the morning Wednesday, before settling into a range. Shares finished with a loss of 0.41 at $19.98.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.